Cover
Cover - shares | 6 Months Ended | |
Mar. 31, 2024 | May 14, 2024 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Document Period End Date | Mar. 31, 2024 | |
Document Fiscal Period Focus | Q2 | |
Document Fiscal Year Focus | 2024 | |
Current Fiscal Year End Date | --09-30 | |
Entity File Number | 333-250025 | |
Entity Registrant Name | Medicale Corp. | |
Entity Central Index Key | 0001827855 | |
Entity Tax Identification Number | 98-1556944 | |
Entity Incorporation, State or Country Code | NV | |
Entity Address, Address Line One | 9314 Forest Hill Blvd #92 | |
Entity Address, City or Town | Wellington | |
Entity Address, State or Province | FL | |
Entity Address, Postal Zip Code | 33411 | |
City Area Code | 407 | |
Local Phone Number | 245-7339 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | true | |
Elected Not To Use the Extended Transition Period | true | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 5,920,000 |
Condensed Balance Sheets (Unaud
Condensed Balance Sheets (Unaudited) - USD ($) | Mar. 31, 2024 | Sep. 30, 2023 |
Current Assets | ||
Cash | $ 159 | $ 159 |
Total Current Assets | 159 | 159 |
Total Assets | 159 | 159 |
Current Liabilities | ||
Related party advances | 0 | 20,480 |
Accounts payable and accrued expenses | 962 | 8,399 |
Current liabilities from discontinued operations | 12,000 | 12,000 |
Total Current Liabilities | 12,962 | 40,879 |
Long term Liabilities | ||
Non-Current Convertible Note Payable | 58,788 | 0 |
Total Long-term Liabilities | 58,788 | 0 |
Total Liabilities | 71,750 | 40,879 |
Stockholders’ Deficit | ||
Common stock, par value $0.0001; 75,000,000 shares authorized, 5,920,000 shares issued and outstanding at March 31, 2024, and September 30, 2023 | 592 | 592 |
Additional paid-in capital | 76,320 | 76,320 |
Accumulated deficit | (148,503) | (117,632) |
Total Stockholders’ Deficit | (71,591) | (40,720) |
Total Liabilities and Stockholders’ Deficit | $ 159 | $ 159 |
Condensed Balance Sheets (Una_2
Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares | Mar. 31, 2024 | Sep. 30, 2023 |
Statement of Financial Position [Abstract] | ||
Common Stock, Par or Stated Value Per Share | $ 0.0001 | $ 0.0001 |
Common Stock, Shares Authorized | 75,000,000 | 75,000,000 |
Common Stock, Shares, Issued | 5,920,000 | 5,920,000 |
Common Stock, Shares, Outstanding | 5,920,000 | 5,920,000 |
Statements of Operations
Statements of Operations - USD ($) | 3 Months Ended | 6 Months Ended | ||
Mar. 31, 2024 | Mar. 31, 2023 | Mar. 31, 2024 | Mar. 31, 2023 | |
Income Statement [Abstract] | ||||
General and Administrative Expenses | $ 10,603 | $ 6,115 | $ 29,910 | $ 14,829 |
NET LOSS FROM OPERATIONS | (10,603) | (6,115) | (29,910) | (14,829) |
Other expenses | ||||
Interest expense | 961 | 0 | 961 | 0 |
TOTAL OTHER EXPENSES | 961 | 0 | 961 | 0 |
Loss before taxes | (11,564) | (6,115) | (30,871) | (14,829) |
Provision for taxes | 0 | 0 | 0 | 0 |
Loss from continuing operations | 0 | 0 | 0 | 0 |
Income (loss) from discontinued operations | 0 | 0 | 0 | 455 |
NET LOSS | $ (11,564) | $ (6,115) | $ (30,871) | $ (14,374) |
Statements of Operations (Paren
Statements of Operations (Parenthetical) - $ / shares | 3 Months Ended | 6 Months Ended | ||
Mar. 31, 2024 | Mar. 31, 2023 | Mar. 31, 2024 | Mar. 31, 2023 | |
Income Statement [Abstract] | ||||
Income (Loss) from Continuing Operations, Per Basic Share | $ 0 | $ 0 | $ 0 | $ 0 |
Income (Loss) from Continuing Operations, Per Diluted Share | 0 | 0 | 0 | 0 |
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share | 0 | 0 | (0.01) | 0 |
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share | $ 0 | $ 0 | $ (0.01) | $ 0 |
Weighted Average Number of Shares Outstanding, Basic | 5,920,000 | 5,920,000 | 5,920,000 | |
Weighted Average Number of Shares Outstanding, Diluted | 5,920,000 | 5,920,000 | 5,920,000 | 5,920,000 |
Statement of Stockholders Equit
Statement of Stockholders Equity (Unaudited) - USD ($) | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total |
Beginning balance, value at Sep. 30, 2022 | $ 592 | $ 25,128 | $ (80,494) | $ (54,774) |
Shares, Outstanding, Beginning Balance at Sep. 30, 2022 | 5,920,000 | |||
Debt forgiveness by related party | 51,192 | 51,192 | ||
Net loss | (8,259) | (8,259) | ||
Ending balance, value at Dec. 31, 2022 | $ 592 | 76,320 | (88,753) | (11,841) |
Shares, Outstanding, Ending Balance at Dec. 31, 2022 | 5,920,000 | |||
Beginning balance, value at Sep. 30, 2022 | $ 592 | 25,128 | (80,494) | (54,774) |
Shares, Outstanding, Beginning Balance at Sep. 30, 2022 | 5,920,000 | |||
Net loss | (14,374) | |||
Ending balance, value at Mar. 31, 2023 | $ 592 | 76,320 | (94,868) | (17,956) |
Shares, Outstanding, Ending Balance at Mar. 31, 2023 | 5,920,000 | |||
Beginning balance, value at Dec. 31, 2022 | $ 592 | 76,320 | (88,753) | (11,841) |
Shares, Outstanding, Beginning Balance at Dec. 31, 2022 | 5,920,000 | |||
Net loss | (6,115) | (6,115) | ||
Ending balance, value at Mar. 31, 2023 | $ 592 | 76,320 | (94,868) | (17,956) |
Shares, Outstanding, Ending Balance at Mar. 31, 2023 | 5,920,000 | |||
Beginning balance, value at Sep. 30, 2023 | $ 592 | 76,320 | (117,632) | (40,720) |
Shares, Outstanding, Beginning Balance at Sep. 30, 2023 | 5,920,000 | |||
Net loss | (19,307) | (19,307) | ||
Ending balance, value at Dec. 31, 2023 | $ 592 | 76,320 | (136,939) | (60,027) |
Shares, Outstanding, Ending Balance at Dec. 31, 2023 | 5,920,000 | |||
Beginning balance, value at Sep. 30, 2023 | $ 592 | 76,320 | (117,632) | (40,720) |
Shares, Outstanding, Beginning Balance at Sep. 30, 2023 | 5,920,000 | |||
Net loss | (30,871) | |||
Ending balance, value at Mar. 31, 2024 | $ 592 | 76,320 | (148,503) | (71,591) |
Shares, Outstanding, Ending Balance at Mar. 31, 2024 | 5,920,000 | |||
Beginning balance, value at Dec. 31, 2023 | $ 592 | 76,320 | (136,939) | (60,027) |
Shares, Outstanding, Beginning Balance at Dec. 31, 2023 | 5,920,000 | |||
Net loss | (11,564) | (11,564) | ||
Ending balance, value at Mar. 31, 2024 | $ 592 | $ 76,320 | $ (148,503) | $ (71,591) |
Shares, Outstanding, Ending Balance at Mar. 31, 2024 | 5,920,000 |
Statements of Cash Flows (Unaud
Statements of Cash Flows (Unaudited) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Mar. 31, 2024 | Mar. 31, 2023 | Mar. 31, 2024 | Mar. 31, 2023 | |
CASH FLOWS FROM OPERATING ACTIVITIES | ||||
Net Loss for the period | $ (11,564) | $ (6,115) | $ (30,871) | $ (14,829) |
Net Loss for the period from discontinued operation | 0 | 0 | 0 | 455 |
Changes in assets and liabilities: | ||||
Accounts payable and accrued liabilities | (7,437) | 9,115 | ||
Related party short term advance | (20,480) | 0 | ||
CASH FLOWS USED IN OPERATING ACTIVITIES | (58,788) | (5,259) | ||
CASH FLOWS FROM FINANCING ACTIVITIES | ||||
Proceeds from Convertible note | 58,788 | 0 | ||
Proceeds from related party short term advances | 0 | 5,418 | ||
CASH FLOWS PROVIDED BY FINANCING ACTIVITIES | 58,788 | 5,418 | ||
Net Cash Increase for Period | 0 | 159 | ||
Cash at the beginning of Period | 159 | 0 | ||
Cash at end of Period | $ 159 | $ 159 | 159 | 159 |
SUPPLEMENTAL CASH FLOW INFORMATION: | ||||
Interest paid | 0 | 0 | ||
Non-cash investing and financing activities: | ||||
Debt forgiveness by related party | $ 0 | $ 51,192 |
Pay vs Performance Disclosure
Pay vs Performance Disclosure - USD ($) | 3 Months Ended | 6 Months Ended | ||||
Mar. 31, 2024 | Dec. 31, 2023 | Mar. 31, 2023 | Dec. 31, 2022 | Mar. 31, 2024 | Mar. 31, 2023 | |
Pay vs Performance Disclosure [Table] | ||||||
Net Income (Loss) | $ (11,564) | $ (19,307) | $ (6,115) | $ (8,259) | $ (30,871) | $ (14,374) |
Insider Trading Arrangements
Insider Trading Arrangements | 3 Months Ended |
Mar. 31, 2024 | |
Trading Arrangements, by Individual [Table] | |
Rule 10b5-1 Arrangement Adopted | false |
Non-Rule 10b5-1 Arrangement Adopted | false |
Rule 10b5-1 Arrangement Terminated | false |
Non-Rule 10b5-1 Arrangement Terminated | false |
ORGANIZATION AND NATURE OF BUSI
ORGANIZATION AND NATURE OF BUSINESS | 6 Months Ended |
Mar. 31, 2024 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
ORGANIZATION AND NATURE OF BUSINESS | Note 1 – ORGANIZATION AND NATURE OF BUSINESS MEDICALE CORP (“the Company,”, “we,” “us” or “our”) was incorporated in the State of Nevada on August 17, 2020. We plan to offer consulting services and distribution of the dietary supplements. A dietary supplement is a manufactured product intended to supplement the diet when taken by mouth as a pill, capsule, tablet, or liquid. A supplement can provide nutrients either extracted from food sources or synthetic, individually or in combination, in order to increase the quantity of their consumption. On December 28, 2022, the previous majority shareholder of Medicale Corp. (the “Company”) Borisi Alborovi entered into a stock purchase agreement for the sale of 3,200,000 shares of Common Stock of the Company (the “Shares”) to Magenta Acres, Inc. As a result of the acquisition of the Shares, Magenta Acres Inc. holds approximately 54% of the issued and outstanding shares of Common Stock of the Company, and as such it is able to unilaterally control the election of our board of directors, all matters upon which shareholder approval is required and, ultimately, the direction of our Company. On December 28, 2022, the previous sole officer and director of the Company, Borisi Alborovi, resigned his positions with the Company. Upon such resignations, Chen Zu De was appointed as Chief Executive Officer, Chairman of the Board, Treasurer and Secretary, and Director of the Company. As of the date of this report, the Company had not yet commenced any operations. All activity through the date of this report relates to preserving cash, attempting to raise capital, and continuing the Company’s public reporting. Our principal place of business is located 9314 Forest Hill Blvd #929 Wellington, FL 33411 which is provided to us on a rent free basis by our sole officer and director. Our telephone number is (407) 245-7339. |
GOING CONCERN
GOING CONCERN | 6 Months Ended |
Mar. 31, 2024 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
GOING CONCERN | Note 2 – GOING CONCERN The accompanying financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”), which contemplate continuation of the Company as a going concern. The Company has an accumulated deficit of $ 148,503 117,632 |
SUMMARY OF SIGNIFICANT ACCOUNTI
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 6 Months Ended |
Mar. 31, 2024 | |
Accounting Policies [Abstract] | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | Note 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with the rules and regulations (Regulation S-X) of the Securities and Exchange Commission (the “SEC”) and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The results of operations for the three and six months ended March 31, 2024 are not necessarily indicative of the operating results that may be expected for the year ending September 30, 2024. These unaudited condensed financial statements should be read in conjunction with the September 30, 2023, financial statements and notes thereto. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates. Deferred Offering Costs Financial Accounting Standard Board Accounting Standards Codification number 340-10-S99-1, Other Assets and Deferred Costs Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. Fair Value of Financial Instruments Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 820 "Fair Value Measurement" defines fair value as the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The standards apply to recurring and nonrecurring fair value measurements of financial and non-financial assets and liabilities. The Company determines the fair values of its assets and liabilities based on a fair value hierarchy that includes three levels of inputs that may be used to measure fair value. For The three levels are defined as follows: Level 1: defined as observable inputs such as quoted prices in active markets; Level 2: defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3: defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. Due to its short-term nature, the carrying value of receivables, accounts payable, and advances approximated fair value at December 31, 2023. Revenue Recognition The Company follows the guidance of Accounting Standards Codification (ASC) 606, Revenue from Contracts. ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contracts, which includes (1) identifying the contracts or agreements with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the services it transfers to its clients. All revenue generated by the Company was done so by operations that have been discontinued. Income Taxes Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized. Long-Lived Assets – Intangible Assets We account for our intangible assets in accordance with ASC Subtopic 350-30, General Intangibles Other Than Goodwill, and ASC Subtopic 360-10-05, Accounting for the Impairment or Disposal of Long-Lived Assets. ASC Subtopic 350-30 requires assets to be measured based on the fair value of the consideration given or the fair value of the assets (or net assets) acquired, whichever is more clearly evident and, thus, more reliably measurable. Further, ASC Subtopic 350-30 requires an intangible asset to be amortized over its useful life and for the useful life to be evaluated every reporting period to determine whether events or circumstances warrant a revision to the remaining period of amortization. If the estimate of useful life is changed the remaining carrying amount of the intangible asset is amortized prospectively over the revised remaining useful life. Costs of internally developing, maintaining, or restoring intangible assets are recognized as an expense when incurred. Basic Income (Loss) Per Share The Company computes income (loss) per share in accordance with FASB ASC 260 “Earnings per Share.” Basic loss per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted income (loss) per share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share excludes all potential common shares if their effect is anti-dilutive. As of March 31, 2024, there were no Recent Accounting Pronouncements We have reviewed all the recently issued, but not yet effective, accounting pronouncements and we do not believe any of these pronouncements will have a material impact on the Company. Risks and Uncertainties In December 2020, a novel strain of coronavirus (COVID-19) emerged in Wuhan, Hubei Province, China. While initially the outbreak was largely concentrated in China and caused significant disruptions to its economy, it has now spread to several other countries and infections have been reported globally. The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak, new information which may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time but is anticipated to have a material adverse impact on our business, financial condition and results of operations. Management expects that its business will be impacted to some degree, but the significance of the impact of the COVID-19 outbreak on the Company’s business and the duration for which it may have an impact cannot be determined at this time. Financial Statement Reclassification Certain account balances from prior periods have been reclassified in these financial statements to conform to current period classifications. |
DISCONTINUED OPERATION
DISCONTINUED OPERATION | 6 Months Ended |
Mar. 31, 2024 | |
Discontinued Operations and Disposal Groups [Abstract] | |
DISCONTINUED OPERATION | Note 4 – DISCONTINUED OPERATION Through December 31, 2022, the Company’s primary business was the sale of various consumer products and accessories. As of January 1, 2023, the Company ceased operations. On January 9, 2023, a change in control completed as the Company’s former majority shareholder sold his 3,200,000 shares to an investor group. After the change in control, the Company’s operations are determined by the new investor group. As such, the Company accounted for all of its revenue (loss), liabilities and results of operations up to January 1, 2023 as discontinued operations. The Company has reclassified its previously issued financial statements to segregate the discontinued operations as of the earliest period reported. The following table presents information related to the liabilities that were classified as current liabilities from discontinued operations in our balance sheets: Schedule of discontinued operations - balance sheet March 31, 2024 September 30, 2023 (Unaudited) Current Liabilities Accounts payable and accrued expenses $ 12,000 $ 12,000 Total current liabilities from discontinued operations $ 12,000 $ 12,000 As of March 31 2024 and 2023 the company has not generate any revenue from discontinued operation. |
COMMON STOCK
COMMON STOCK | 6 Months Ended |
Mar. 31, 2024 | |
Equity [Abstract] | |
COMMON STOCK | Note 5 – COMMON STOCK The Company has 75,000,000 0.0001 All shares of common stock have voting rights and are identical. All holders of shares of common stock shall at every meeting of the stockholders be entitled to one vote for each share of the capital stock held by such stockholder. On December 28, 2022, Borisi Alborovi, the previous majority shareholder of Medicale Corp. (the “Company”), entered into a stock purchase agreement for the sale of 3,200,000 shares of Common Stock of the Company (the “Shares”) to Magenta Acres, Inc. As of March 31, 2024 the company had 5,920,000 Voting Common Stock All shares of common stock have voting rights and are identical. All holders of shares of voting common stock shall at every meeting of the stockholders be entitled to one vote for each share of the capital stock held by such stockholder. Non-voting Common Stock All of the other terms of the Non-Voting Common Stock shall be identical to the Voting Common Stock, except for the right of first refusal that attaches to the Non-Voting Common Stock, as explained in the Company’s Bylaws. |
INTANGIBLE ASSETS
INTANGIBLE ASSETS | 6 Months Ended |
Mar. 31, 2024 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
INTANGIBLE ASSETS | Note 6 – INTANGIBLE ASSETS The Company purchased and possesses an asset in a form of an operative website with news blog. The Company purchased the website for $12,000 and was amortizing the asset straight-line over its five-year useful life or $2,400 per year. Due to the impairment evaluation analysis as of September 30, 2022 where we deemed the asset’s carrying amount was not recoverable, we recognized impairment of $ 7,200 nil . |
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES | 6 Months Ended |
Mar. 31, 2024 | |
Commitments and Contingencies Disclosure [Abstract] | |
COMMITMENTS AND CONTINGENCIES | Note 7 – COMMITMENTS AND CONTINGENCIES Management expects that its business will be impacted to some degree, but the significance of the impact of the COVID-19 outbreak on the Company’s business and the duration for which it may have an impact cannot be determined at this time. |
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS | 6 Months Ended |
Mar. 31, 2024 | |
Related Party Transactions [Abstract] | |
RELATED PARTY TRANSACTIONS | Note 8 – RELATED PARTY TRANSACTIONS The sole officer and director, Borisi Alborovi, was the only related party with whom the Company had transactions with during the period from inception on August 17, 2020 through December 31, 2022. On December 28, 2022, the previous sole officer and director, Borisi Alborovi, resigned his positions with the Company. Upon such resignations, Chen Zu De was appointed as Chief Executive Officer, Chairman of the Board, Treasurer and Secretary, and Director of the Company. As a result of the acquisition of the Shares on December 28, 2022, the previous majority shareholder of Medicale Corp. (the “Company”) Borisi Alborovi forgive the debt that due to him, with the amount of $ 51,192 As of December 31, 2023 and September 30, 2023, the Company owed Mr. Alborovi $ nil nil As of March 31, 2024 and September 30, 2023, the Company owed Chen Zu De $ nil nil |
CONVERTIBLE NOTE PAYABLE
CONVERTIBLE NOTE PAYABLE | 6 Months Ended |
Mar. 31, 2024 | |
Debt Disclosure [Abstract] | |
CONVERTIBLE NOTE PAYABLE | Note 9 – CONVERTIBLE NOTE PAYABLE On December 31, 2023, the company entered into a Convertible Note agreement with an third party at $ 21,051 8 December 31, 2029 420 On December 31, 2023, the company entered into a Convertible Note agreement with an third party at $ 27,135 8 December 31, 2029 0.01 541 On March 31, 2024, the company entered into a Convertible Note agreement with an third party at $ 10,602 8 March 31, 2030 nil |
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS | 6 Months Ended |
Mar. 31, 2024 | |
Subsequent Events [Abstract] | |
SUBSEQUENT EVENTS | Note 10 – SUBSEQUENT EVENTS In accordance with SFAS 165 (ASC 855-10) the Company has analyzed its operations subsequent to March 31, 2024 to the date these financial statements were issued and has determined that it does not have any material subsequent events to disclose in these financial statements. |
SUMMARY OF SIGNIFICANT ACCOUN_2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) | 6 Months Ended |
Mar. 31, 2024 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with the rules and regulations (Regulation S-X) of the Securities and Exchange Commission (the “SEC”) and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The results of operations for the three and six months ended March 31, 2024 are not necessarily indicative of the operating results that may be expected for the year ending September 30, 2024. These unaudited condensed financial statements should be read in conjunction with the September 30, 2023, financial statements and notes thereto. |
Use of Estimates | Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates. |
Deferred Offering Costs | Deferred Offering Costs Financial Accounting Standard Board Accounting Standards Codification number 340-10-S99-1, Other Assets and Deferred Costs |
Cash and Cash Equivalents | Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. |
Fair Value of Financial Instruments | Fair Value of Financial Instruments Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 820 "Fair Value Measurement" defines fair value as the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The standards apply to recurring and nonrecurring fair value measurements of financial and non-financial assets and liabilities. The Company determines the fair values of its assets and liabilities based on a fair value hierarchy that includes three levels of inputs that may be used to measure fair value. For The three levels are defined as follows: Level 1: defined as observable inputs such as quoted prices in active markets; Level 2: defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3: defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. Due to its short-term nature, the carrying value of receivables, accounts payable, and advances approximated fair value at December 31, 2023. |
Revenue Recognition | Revenue Recognition The Company follows the guidance of Accounting Standards Codification (ASC) 606, Revenue from Contracts. ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contracts, which includes (1) identifying the contracts or agreements with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the services it transfers to its clients. All revenue generated by the Company was done so by operations that have been discontinued. |
Income Taxes | Income Taxes Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized. |
Long-Lived Assets – Intangible Assets | Long-Lived Assets – Intangible Assets We account for our intangible assets in accordance with ASC Subtopic 350-30, General Intangibles Other Than Goodwill, and ASC Subtopic 360-10-05, Accounting for the Impairment or Disposal of Long-Lived Assets. ASC Subtopic 350-30 requires assets to be measured based on the fair value of the consideration given or the fair value of the assets (or net assets) acquired, whichever is more clearly evident and, thus, more reliably measurable. Further, ASC Subtopic 350-30 requires an intangible asset to be amortized over its useful life and for the useful life to be evaluated every reporting period to determine whether events or circumstances warrant a revision to the remaining period of amortization. If the estimate of useful life is changed the remaining carrying amount of the intangible asset is amortized prospectively over the revised remaining useful life. Costs of internally developing, maintaining, or restoring intangible assets are recognized as an expense when incurred. |
Basic Income (Loss) Per Share | Basic Income (Loss) Per Share The Company computes income (loss) per share in accordance with FASB ASC 260 “Earnings per Share.” Basic loss per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted income (loss) per share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share excludes all potential common shares if their effect is anti-dilutive. As of March 31, 2024, there were no |
Recent Accounting Pronouncements | Recent Accounting Pronouncements We have reviewed all the recently issued, but not yet effective, accounting pronouncements and we do not believe any of these pronouncements will have a material impact on the Company. |
Risks and Uncertainties | Risks and Uncertainties In December 2020, a novel strain of coronavirus (COVID-19) emerged in Wuhan, Hubei Province, China. While initially the outbreak was largely concentrated in China and caused significant disruptions to its economy, it has now spread to several other countries and infections have been reported globally. The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak, new information which may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time but is anticipated to have a material adverse impact on our business, financial condition and results of operations. Management expects that its business will be impacted to some degree, but the significance of the impact of the COVID-19 outbreak on the Company’s business and the duration for which it may have an impact cannot be determined at this time. |
Financial Statement Reclassification | Financial Statement Reclassification Certain account balances from prior periods have been reclassified in these financial statements to conform to current period classifications. |
DISCONTINUED OPERATION (Tables)
DISCONTINUED OPERATION (Tables) | 6 Months Ended |
Mar. 31, 2024 | |
Discontinued Operations and Disposal Groups [Abstract] | |
Schedule of discontinued operations - balance sheet | Schedule of discontinued operations - balance sheet March 31, 2024 September 30, 2023 (Unaudited) Current Liabilities Accounts payable and accrued expenses $ 12,000 $ 12,000 Total current liabilities from discontinued operations $ 12,000 $ 12,000 |
GOING CONCERN (Details Narrativ
GOING CONCERN (Details Narrative) - USD ($) | Mar. 31, 2024 | Sep. 30, 2023 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
Retained Earnings (Accumulated Deficit) | $ 148,503 | $ 117,632 |
SUMMARY OF SIGNIFICANT ACCOUN_3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) | 3 Months Ended |
Mar. 31, 2024 shares | |
Accounting Policies [Abstract] | |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 0 |
Discontinued Operations (Detail
Discontinued Operations (Details - Balance Sheet) - USD ($) | Mar. 31, 2024 | Sep. 30, 2023 |
Discontinued Operations and Disposal Groups [Abstract] | ||
Accounts payable and accrued expenses | $ 12,000 | $ 12,000 |
Total current liabilities from discontinued operations | $ 12,000 | $ 12,000 |
COMMON STOCK (Details Narrative
COMMON STOCK (Details Narrative) - $ / shares | Mar. 31, 2024 | Sep. 30, 2023 |
Equity [Abstract] | ||
Common Stock, Shares Authorized | 75,000,000 | 75,000,000 |
Common Stock, Par or Stated Value Per Share | $ 0.0001 | $ 0.0001 |
Common Stock, Shares, Issued | 5,920,000 | 5,920,000 |
Common Stock, Shares, Outstanding | 5,920,000 | 5,920,000 |
INTANGIBLE ASSETS (Details Narr
INTANGIBLE ASSETS (Details Narrative) - USD ($) | 12 Months Ended | ||
Sep. 30, 2022 | Mar. 31, 2024 | Sep. 30, 2023 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |||
Asset Impairment Charges | $ 7,200 | ||
Finite-Lived Intangible Assets, Net | $ 0 | $ 0 |
RELATED PARTY TRANSACTIONS (Det
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($) | 6 Months Ended | 12 Months Ended | |||
Mar. 31, 2024 | Mar. 31, 2023 | Dec. 28, 2022 | Dec. 31, 2023 | Sep. 30, 2023 | |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Debt Forgiveness by Related Party | $ 0 | $ 51,192 | $ 51,192 | ||
Alborovi [Member] | |||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Accounts Payable, Other, Current | $ 0 | $ 0 | |||
Zu [Member] | |||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||||
Accounts Payable, Other, Current | $ 0 | $ 0 |
CONVERTIBLE NOTE PAYABLE (Detai
CONVERTIBLE NOTE PAYABLE (Details Narrative) - USD ($) | 3 Months Ended | |
Mar. 31, 2024 | Dec. 31, 2023 | |
Convertible Note 1 [Member] | ||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||
Convertible Notes Payable | $ 21,051 | |
Debt Instrument, Interest Rate During Period | 8% | |
Accrued Interest on Convertible Notes Payable | $ 420 | |
Convertible Note 2 [Member] | ||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||
Convertible Notes Payable | $ 27,135 | |
Debt Instrument, Interest Rate During Period | 8% | |
Debt Instrument, Maturity Date | Dec. 31, 2029 | |
Accrued Interest on Convertible Notes Payable | 541 | |
Debt Instrument, Convertible, Conversion Price | $ 0.01 | |
Convertible Note 3 [Member] | ||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||
Convertible Notes Payable | $ 10,602 | |
Debt Instrument, Interest Rate During Period | 8% | |
Debt Instrument, Maturity Date | Mar. 31, 2030 | |
Accrued Interest on Convertible Notes Payable | $ 0 |